Hikal credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
681681762815748
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
667667744794688
0.57×0.57×0.60×0.69×0.66×
0.56×0.56×0.59×0.67×0.61×
3.09×3.09×2.32×3.05×2.91×
2.87×3.03×2.27×2.97×2.68×
0.91×0.91×2.58×2.65×3.08×
36.2%36.2%37.7%40.7%39.8%
As filed — company-reported covenants
0.53×0.56×0.59×——
1.23×1.22×1.45×——
3.82×3.76×4.00×——
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HIKAL₹202.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,496 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt748.0814.7762.3681.1681.1
Net Debt688.4793.9744.3667.3667.3
Total Debt/Equity0.660.690.600.570.57
Net Debt/Equity0.610.670.590.560.56
Total Debt/EBITDA2.913.052.323.093.09
Net Debt/EBITDA2.682.972.273.032.87
Interest Coverage (EBIT/Interest)3.082.652.580.910.91
Total Debt/Total Capital %39.7540.6937.6536.2336.23
As Filed — company-reported covenants
Debt/Equity (as filed)——0.590.560.53
Debt Service Coverage (as filed)——1.451.221.23
Interest Service Coverage (as filed)——4.003.763.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.